| Accuracy and Precision Evaluation of Seven Self-Monitoring Blood Glucose Systems. | |
| | |
MedLine Citation:
|
PMID: 21406013 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Abstract Background: Self-monitoring blood glucose (SMBG) systems play a critical role in management of diabetes. SMBG systems should at least meet the minimal requirement of the World Health Organization's ISO 15197:2003. For tight glycemic control, a tighter accuracy requirement is needed. Methods: Seven SMBG systems were evaluated for accuracy and precision: Bionime Rightest(™) GM550 (Bionime Corp., Dali City, Taiwan), Accu-Chek(®) Performa (Roche Diagnostics, Indianapolis, IN), OneTouch(®) Ultra(®)2 (LifeScan Inc., Milpitas, CA), MediSense(®) Optium(™) Xceed (Abbott Diabetes Care Inc., Alameda, CA), Medisafe (TERUMO Corp., Tokyo, Japan), Fora(®) TD4227 (Taidac Technology Corp., Wugu Township, Taiwan), and Ascensia Contour(®) (Bayer HealthCare LLC, Mishawaka, IN). The 107 participants (44 men and 63 women) were between 23 and 91 years old. The analytical results of seven SMBG systems were compared with those of plasma analyzed with the hexokinase method (Olympus AU640, Olympus America Inc., Center Valley, PA). Results: The imprecision of the seven blood glucose meters ranged from 1.1% to 4.7%. Three of the seven blood glucose meters (42.9%) fulfilled the minimum accuracy criteria of ISO 15197:2003. The mean absolute relative error value for each blood glucose meter was calculated and ranged from 6.5% to 12.0%. Conclusions: More than 40% of evaluated SMBG systems meet the minimal accuracy criteria requirement of ISO 15197:2003. However, considering tighter criteria for accuracy of ±15%, only the Bionime Rightest GM550 meets this requirement. Because SMBG systems play a critical role in management of diabetes, manufacturers have to strive to improve accuracy and precision and to ensure the good quality of blood glucose meters and test strips. |
| | |
Authors:
|
Chih-Yi Kuo; Cheng-Teng Hsu; Cheng-Shiao Ho; Ting-En Su; Ming-Hsun Wu; Chau-Jong Wang |
Related Documents
:
|
9822973 - Effect of hyperbaric oxygen on ophthalmic artery blood velocity in patients with diabet... 3071993 - Diabetic amyotrophy: reassessment of the clinical spectrum. 16093923 - Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzym... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-3-15 |
Journal Detail:
|
Title: Diabetes technology & therapeutics Volume: - ISSN: 1557-8593 ISO Abbreviation: - Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-3-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100889084 Medline TA: Diabetes Technol Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
1 Department of Clinical Laboratory, Tai-An Hospital , Taichung, Taiwan . |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of Capillary Whole Blood Versus Venous Plasma Glucose Estimations in Screening for Diabet...
Next Document: The Effect of Liraglutide Added to U-500 Insulin in Patients with Type 2 Diabetes and High Insulin R...